Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Peripheral Artery Disease
In brief
This study was designed to assess the safety, tolerability and efficacy of ACZ885 on the leg artery structure and physical activity in patients with atherosclerotic peripheral artery disease and leg pain from walking.
Key facts
- Study ID
- NCT01731990
- Run by
- Novartis Pharmaceuticals
- People needed
- 38
- Starts
- 2012-10-30
- Expected to finish
- 2016-08-04
- Last updated by the study team
- 2025-04-29
Who can join
Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — Phoenix, Arizona, United States
- Novartis Investigative Site — Jacksonville, Florida, United States
- Novartis Investigative Site — Jacksonville, Florida, United States
- Novartis Investigative Site — Chicago, Illinois, United States
- Novartis Investigative Site — Lutherville, Maryland, United States
- Novartis Investigative Site — Columbus, Ohio, United States
- Novartis Investigative Site — Knoxville, Tennessee, United States
- Novartis Investigative Site — Richmond, Virginia, United States
- Novartis Investigative Site — Hamburg, Germany
- Novartis Investigative Site — Hamburg, Germany
- Novartis Investigative Site — Heidelberg, Germany
- Novartis Investigative Site — Mainz, Germany
- Novartis Investigative Site — München, Germany
- Novartis Investigative Site — Amman, Jordan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.